Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Inclusion Criteria

• •Subject must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained
• •Subjects with a histologic diagnosis of unresectable stage IV melanoma (may include mucosal melanoma)
• •Tumor must be BRAF V600E mutation positive from a certified lab
• •At least 4 weeks since any previous treatment (surgery, radiotherapy, or systemic treatment)
• •Women should be either: post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing a reliable form of contraception during the study and for at least 4 months after the final study drug infusion or ingestion; women of childbearing potential must have a negative serum hCG-beta pregnancy test conducted during the screening period
• •Men who may father a child must agree to the use of male contraception for the duration of their participation in the trial and for at least 4 months after the final temsirolimus and AZD6244 hydrogen sulfate administration
• •Life expectancy \>= 3 months
• •ECOG performance status of 0 or 1
• •Patients with brain metastases treated with surgery, radiation, or stereotactic radiosurgery who are without evidence of progression in their brain metastases after MRI imaging performed at least 30 days after treatment, and are not taking systemic steroids will be eligible
• •WBC \>= 3000 cells/mm\^3
• •ANC \>= 1500 cells/mm\^3
• •Platelets \>= 100,000/mm\^3
• •Hematocrit \>= 30%
• •Hemoglobin \>= 9 g/dL
• •Creatinine =\< 2.0 mg/dL
• •AST/ALT =\< 2 x ULN
• •Bilirubin =\< 1.5 x ULN, (except subjects with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dL)
• •HIV negative
• •HBsAg negative
• •Anti-HCV Ab nonreactive; if reactive, subject must have a negative HCV RNA qualitative PCR
• •Patients with hyperlipidemia must have adequate control with a lipid lowering agent